Tanja Obradovic: Two practice-changing trials of Keytruda within Presidential Symposium of ESMO24

Tanja Obradovic shared on LinkedIn:

“ESMO 2024 will have two practice-changing trials of Keytruda (Pembrolizumab) presented within Presidential Symposium. We’ll see first time OS results from Phase III Keynote-522 trial of Keytruda in combination with chemotherapy as neoadjuvant treatment and then continuing as single agent adjuvant in TNBC patients with high-risk early-stage disease.

Also, OS from the Phase III Keynote-A18 trial evaluating Keytruda in combination with concurrent chemoradiotherapy (CRT) as treatment for patients with high-risk locally advanced cervical cancer. Amazing success for Merck Women’s cancer team and testament to outstanding leadership of immunooncology expert Gursel Aktan and her absolute commitment to cancer patients! Congratulations!”

Read Further.
Source: Tanja Obradovic/LinkedIn

More posts featuring Tanja Obradovic on oncodaily.com

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.